Backgrounds/Aims: Graft survival after ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has increased due to advances in desensitization methods. We analyzed early outcomes following ABOi LDLT using only rituximab without any additional desensitization methods in recipients with low anti-ABO antibody titers (≤1:32). Methods: Ten adult patients underwent ABOi LDLT between September 2014 and December 2016. All patients were administered a single dose of rituximab (300 mg/m 2 ) prior to LDLT. Three patients with baseline anti-ABO titer ＞1:32 underwent multiple sessions of plasmapheresis to reduce titers to ＜1:32 (rituximab+plasmapheresis, RP). Seven patients with low anti-ABO titer (≤1:32) did not undergo plasmapheresis (rituximab-only, RO). ABO-compatible LDLT patients during the same period were included for comparison (n=22). Results: Post-transplantation titers were significantly lower in the RO than in the RP and showed no rebound rise (POD7 1.14±0.38 vs 28.0±31.7, p=0.04), (POD30 1.26±0.45 vs 108±107, p=0.02). There were no significant differences in rejection, biliary complications and infection between groups. There were no significant differences in outcome between the RO group and ABO-compatible except for infection. Conclusions: This study shows that recipients with low baseline anti-ABO antibody titer (≤1:32) can undergo ABOi LDLT using conventional immunosuppression and rituximab alone. 
Plasmapheresis (PP) plays an important role in ABOi
LDLT by lowering anti-ABO antibody titer before and after transplantation. Egawa et al. 2 have reported that all long-term survivors showed lower levels of anti-ABO antibody titers, while Ashizawa et al. 3 reported that elevation of anti-ABO antibody titers after transplantation may be a predictive risk factor for increased transplantationrelated mortality and morbidity. Plasmapheresis is an indispensable treatment for improving the outcomes of ABOi LT.
However, plasmapheresis for liver transplantation is classified as category III 4 according to the American Society for Apheresis guidelines (Category III: optimum role of apheresis therapy is not established; decision-making should be individualized). Because the procedure requires a largebore catheter and is necessarily invasive, some complications inevitably arise. The complication rate of plasmapheresis in LDLT patients is estimated at 25-40%. 5 
PATIENTS AND METHODS

Patients
Ten patients underwent adult ABOi LDLT (age ＞18 years) and twenty-two patients underwent adult ABO- To identify rejection after transplantation, we performed routine protocol liver biopsy and CT scan at postoperative day 7. ACR biopsy specimens were graded using Banff schema, the international standard for grading acute liver allograft rejection. This schema is composed of two parts, the global assessment (GA) and the rejection activity index (RAI). 9 We determined the presence of acute AMR histopathologically, using the Banff criteria (including the 
Rejection and complications
following
Statistical analysis
All statistical analyses were performed by using IBM SPSS Statistics ver. 18.0 (IBM Co., Armonk, NY, USA).
Patient demographics are expressed as median (range).
The Mann-Whitney U test was used for comparisons between the ABOi and ABOc LDLTs. Table 1 . There were no significant differences between the RO group and RP group.
RESULTS
Patient characteristics
The RO group showed slightly higher mean pre-transplant showed a relatively high level of baseline serum CD19+ lymphocytes, it was effectively suppressed after administration of a single dose of RTX before transplantation.
Patients belonging to the RP group received an average of three cycles of plasmapheresis.
ii) ABOi LDLT (rituximab-only, RO) versus ABOc LDLT There was no significant difference in the general characteristics of the RTX-only ABOi group and the ABOc group (Table 3) .
Changes in the CD19+ B-cell ratio and anti-ABO antibody titers in the ABOi group i) Change in CD19+ counts
There was no significant difference in initial (baseline 
ii) Changes in anti-ABO antibody titers
The changes in the anti-ABO antibody titers in ABOi LDLT are shown in Fig. 3 . The average initial anti-ABO antibody titer was 20.0±21.5 in the RO group and 213± 73.9 in RP group. Because plasmapheresis was not performed in the low anti-ABO antibody titer group (≤1:32), the initial anti-ABO antibody titer was significantly lower There were no significant differences in transplantationrelated complications between the RO group and RP group (Table 4) . The biliary anastomosis site stricture and biliary anastomosis site leakage rate (≥IIIa, Clavin-Dindo classification) of the RO group were 28.6% and 28.6%, respectively. However, there were no significant differences between the RO group and RP group (p=0.40). All patients were treated with endoscopic retrograde biliary stenting or percutaneous trans-hepatic cholangiographic drainage. There were no cases of diffuse intrahepatic biliary stricture (DIHBS) in either group. There were no significant differences in infection complications between the two groups (p=0.50).
ii) ABOi LDLT (rituximab-only, RO) versus ABOc LDLT When comparing the early outcomes between RO group ABOi LDLT and ABOc LDLT, there were no significant differences between the two groups except for infection rate. (RO group ABOi, 57.1%; ABOc, 9.1%; p=0.02; Table 5 ). In the RO group, two patients experienced pneumonia and two experienced cholangitis. The 30-day patient and graft survival of the RO group was 100%. However, one patient in the ABOc group died because of primary graft failure on post-operative day 7.
Rejection
No acute AMR occurred in either the ABOi or ABOc LDLT group. In the RO group, one patient developed ACR. The liver needle biopsy on post-operative day 7
showed mild infiltration of lymphocytes and a few neutrophils in most portal tracts (RAI=5). Rejection therapy was performed because the hepatic enzyme levels were elevated. After the steroid pulse therapy, the histology showed improvement on post-operative day 13. In the case of the ABOc LDLT group, only ACR occurred (n=2, 9.1%). Both patients were treated with steroid pulse therapy and adjustment of immunosuppressant.
DISCUSSION
We report our early experiences that recipients with low baseline anti-ABO antibody titers can successfully undergo ABOi LDLT using only rituximab without plasmapheresis. Although ABOi graft survival has been improved with desensitization, AMR is still considered a difficult problem. A previous study reported that the incidence of AMR decreased from 23.5% to 6.2% after the introduction of RTX. 7 In our cases, acute AMR did not occur in either the RTX-only or RTX+PP ABOi LDLT group. Additionally, during the follow-up period, there was no death in the ABOi LDLT group (median follow-up period: 22 months).
Since the pre-formed anti-ABO antibody was demonstrated to mediate hyperacute or severe rejection in ABOi LDLT, 9 there have been several reports regarding the relationship between anti-ABO antibody titer and acute AMR.
Because the presence of anti-ABO antibody in the recipient is a risk for AMR, reducing antibody levels plays a key role in the success of the transplantation. 10 Another study reported that high preoperative antibody titer did not have a significant effect on AMR, instead emphasizing the importance of preventing new antibody production after There was no significant difference in LT-related complications between the RO group and RP group. In addition, the RO group showed low anti-ABO antibody titer after transplantation and did not show a rebound rise of antibody titer after transplantation. AMR has been observed in ABOi KT patients with a high baseline titer. 15 Despite conflicting views regarding the importance of baseline anti-ABO antibody titers in ABOi LT, our finding that post-transplant antibody levels remained low in patients with low baseline levels indicate that baseline anti-ABO antibody titer is likely to be more important than preoperative titer in determining outcomes.
RTX has increased the graft survival following ABOi.
Despite its clear utility, it may have disadvantages as well.
The increased incidence of infection we observed in the RO ABOi group relative to the ABOc group was also reported in another study. 8 However, this differs from the results of Egawa et al., who reported no significant differences between the incidence of bacterial infection or CMV disease between RTX and non-RTX groups. 16 Fur-ther research is warranted to investigate the relationship of RTX to infection rates.
This study has several limitations. First, our necessarily small sample size limited robustness, Further studies including larger numbers of patients are needed Second, because the follow-up period of the current study was relatively short, results of a long-term follow-up are needed.
Third, since the standard anti-ABO antibody target titer before transplantation has not been established yet, the criteria for low titer (≤1:32) have been set by our center.
In conclusion, LDLT recipients with low baseline anti-ABO antibody titer (≤1:32) can successfully undergo ABOi LDLT using conventional immunosuppression and rituximab alone.
